Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 126 Next >>

Filter Applied: adverse drug reaction (Click to remove)

Muscle Cramps
Arch Int Med 150:511-518, McGee,S.R., 1990

Rabbit Syndrome
Neurol102:e209275, Huynh,T.U., & Beckley, E.H., 2024

Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023

Trial of Botulinum Toxin for Isolated or Essential Head Tremor
NEJM 389:1753-1765, Marques,A.,et al, 2023

A 59-Year-Old Woman Presenting with Diplopia, Dysarthria, Right-sided Weakness, and Encephalopathy
Neurol 97:e859-e864, Manzano, G.S.,et al, 2021

Tardive Diaphragmatic Tremor
Neurol 94:e656, Gupta, H.V., 2020

Burning Pain in the Legs
NEJM 383:e18, Sacks, C.A., 2020

A 54-year-old woman with Dementia, Myoclonus, and Ataxia
Neurol 89:e7-e12, Ali, F.,et al, 2017

Clinicopathologic Conference, Copper Deficiency Myelopathy
NEJM 377:1977-1984, Case 35-2017, 2017

Restless Legs Syndrome Associated with Major Diseases
Neurol 86:1336-1343, Trenkwalder, C.,et al, 2016

Corticosteroid-Induced Paraplegia - A Diagnostic Clue for Spinal Dural Arterial Venous Fistula
JAMA Neurol 72:833-834, Hocker, S., 2015

Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014

Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014

Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014

Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Antipsychosis Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1208, Ropper, A.H.,et al, 2014

Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Serotonin Reuptake Inhibitors and Related Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1212, Ropper, A.H.,et al, 2014

Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Lithium
Adams & Victors Principles of Neurology Chp 43, pg 1212, Ropper, A.H.,et al, 2014

Neurostimulation for Parkinsons Disease with Early Motor Complications
NEJM 368:610-622, Rau, W.,et al, 2013

Clinicopathologic Conference,Necrotizing Noninflammatory Myopathy Consistent with Exposure to Statins
NEJM 36:944-954, Case 7-2012, 2012

Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011

Evidence-based guideline update: Treatment of Essential Tremor
Neurol 77:1752-1755, Zesiewicz, T.A.,et al, 2011

Assessment: Symptomatic Treatment for Muscle Cramps (an Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:691-696, Katzberg,H.D.,et al, 2010

Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity
Arch Neurol 66:865-869, Orr,C.F. &Ahlskog,E., 2009

Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009

Polymyalgia Rheumatica
BMJ 336:765-769, Michet,C.J. &Matteson,E.L., 2008

Reversible Parkinsonism and Ataxia Associated With High-Dose Octreotide
Neurol 70:2345-2346, Espay,A.J., 2008

Pathologic Gambling in Patients with Restless Legs Syndrome Treated With Dopaminergic Agonists
Neurol 68:301-303, Tippmann-Peikert,M.,et al, 2007

Clinical Update:Diagnosis and Treatment of Essential Tremor
Lancet 369:1152-1154, Benito-Leon,J&Louis,E.D., 2007

Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Arch Neurol 64:820-824, Kleiner-Fisman,G. &Fisman,D.N., 2007

Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007

A 75-Year-Old Man With Cognitive Impairment and Gait Changes, Lewy Body Disease
Neurol 69:1183-1189, Lippa,C.F.,et al, 2007

Cetirizine-Induced Dystonic Movements
Neurol 66:143-144, Rajput,A. &Baerg,K., 2006

What is the Risk of Developing Parkinsonism Following Neuroleptic Use?
Neurol 66:941-943, Noyes,K.,et al, 2006

Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006

The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005

Reversible Parkinsonism with Normal B-CIT-SPECT in Patients Exposed to Sodium Valproate
Neurol 62:1435-1437, Easterford,K.,et al, 2004

Zonisamide-Induced Restless Legs Syndrome
Neurol 60:147, Chen,J.T.,et al, 2003

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate, III. Initial Therapy in a Total of 55 Neurologically Affected Patients and Follow-up With Zinc Therapy
Arch Neurol 60:379-385, Brewer,G.J.,et al, 2003

Statin-Associated Myopathy
JAMA 289:1681-1690, Thompson,P.D.,et al, 2003

Clinicopath Conf., Colchicine Myoneuropathy
NEJM 349:1656-1663, Case 33-2003, 2003

The Risk-Benefit Profile of Commonly Used Herbal Therapies: Ginkgo, St. John's Wort, Genseng, Echinacea, Saw Palmetto, and Kava
Ann Int Med 136:42-53, Ernst,E., 2002

A Double-blind Placebo-controlled Trial of Topiramate Treatment for Essential Tremor
Neurol 59:132-134, Connor,G.S., 2002

Drug-Induced Pisa Syndrome (Pleurothotomus)
CNS Drugs 10:166-174, Suzuki, T. & Matsuzaka, H., 2002

Myoclonus Secondary to Albuterol (Salbutamol) instillation
Neurol 54:2022-2023, Micheli,F.,et al, 2000

Clinical Characteristics of Pramipexole-Induced Peripheral Edema
Arch Neurol 57:729-732, Tan,E.K.&Ondo,W., 2000

A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000

A Case of Lithium-Induced Asterixis
J Am Geriatr Society 48:457, Stewart,J.T. & Williams, L.S., 2000

Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000

Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease
JAMA 284:1931-1938,1971, Parkinson Study Group, 2000



Showing articles 0 to 50 of 126 Next >>